-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Upgrades Design Therapeutics to Outperform, Raises Price Target to $13

Benzinga·11/20/2025 15:03:16
Listen to the news
RBC Capital analyst Leonid Timashev upgrades Design Therapeutics (NASDAQ:DSGN) from Sector Perform to Outperform and raises the price target from $6 to $13.